Clinical Trials Browser

Active not recruiting × orelabrutinib × 90 days × Clear all

NCT07480863 2026-03-18

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone

NCT06583837 2026-02-27

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone